Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets genetic weakness in deadly brain tumor

NCT ID NCT06105619

Disease control Sponsor: Beijing Pearl Biotechnology Limited Liability Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This clinical trial tests a new drug called vebreltinib (PLB1001) in people with a recurrent form of glioblastoma that has a specific genetic change (ZM fusion gene). The study compares vebreltinib to standard chemotherapy to see if it helps people live longer. About 84 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vebreltinib (PLB1001)
What this could lead to
If successful, this could provide a new targeted treatment option for people with a specific genetic subtype of recurrent glioblastoma, potentially improving survival.
What could go wrong
This is an early-to-mid-stage trial with only 84 participants. The drug may not prove more effective than standard chemotherapy, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

84 people

The number who actually took part.

Started

Oct 2018

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. histologically confirmed secondary glioblastoma,or glioblastoma with IDH mutantation 2. Must have evidence of PRPRZ1-MET fusion gene positivity from the result of molecular pre-screening evaluations 3. Prior treatment with temozolomide and radiotherapy 4. Stable or decreasing dose of corticosteroids within 5 days prior to the first dose 5. Platelet count≥75×109/L,Neutrophilic granulocyte count≥1.5×109/L, Hemoglobin\>90g/L,AST or ALT \< 3 times the lab's upper normal limit,Serum creatinine \< 1.5 times the lab's upper normal limit,INR≤2.0 6. Karnofsky performance score ≥ 60% 7. Pregnant or nursing women 8. Written consent Exclusion Criteria: 1. Previous or current treatment with a c-Met inhibitor or HGF-targeting therapy 2. Received antibody anti-tumor drug within 30 days before enrollment 3. Previous treatment with Camustine sustained release implant 4. The subject is unable to undergo MRI scan 5. Patients with active bleeding were found by brain CT or MRI scan before enrollment 6. Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) 150 mm Hg and/or Diastolic Blood Pressure (DBP) ≥100 mm Hg 7. Major surgery within 4 weeks prior to first dose of PLB1001 8. Pregnant or nursing women 9. Involved in other clinical trials \<30 days prior to first dose

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 4 glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma

Contacts and locations

Locations

  • Beijing Tiantan Hospital,Capital Medical University

    Beijing, Beijing Municipality, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.